International Clinical Trial: GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/?)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738341) titled 'GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/?)' on July 23.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Eddingpharm (Zhuhai) Co., Ltd.

Condition: Breast Cancer (Locally Advanced or Metastatic)

Intervention: Drug: Sacituzumab Tirumotecan Drug: GB268 Drug: Nab-Paclitaxel

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: August 1, 2026

Target Sample Size: 270

To know more, visit https...